Giancarlo Bizzarri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Giancarlo Bizzarri has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Enrico Papini
Regina Apostolorum Hospital – Lifenethealth Group
3 shared publications - Irene Misischi
Department of Endocrinology, Regina Apostolorum Hospital, Albano, Rome, Italy
2 shared publications - Andrea Frasoldati
Endocrinology Unit, Arcispedale S. Maria Nuova IRCCS – ASL Reggio Emilia
1 shared publication - Angela Valentina D’elia
Department of Medical and Biological Sciences, University of Udine, Udine, Italy
1 shared publication - Anna Crescenzi
Sapienza University of Rome
1 shared publication - Annibale Versari
Santa Maria Nuova Hospital IRCCS
1 shared publication
Latest Publications
- Open Access
- 20 July 2014
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 37 (9) , 875-909
Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
- 20 July 2014
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 37 (9) , 875-909
Open AccessItalian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
Long-term efficacy of ultrasound-guided laser ablation for solid thyroid nodules. A three-year multicenter prospective randomized trial
Background: Thermal ablation techniques are reported to significantly decrease thyroid nodule volume in several single-center short-term series. The present trial on ultrasound (US)-guided laser ablation (LAT) of solid thyroid nodules is addressed to assess long-term clinical efficacy, side-effects and variability of outcomes in different centers operating with the same LAT procedure. Patients: Two hundred and one consecutive patients were randomly assigned to a single LAT session (Group 1) or follow-up (Group 2) at four thyroid referral centers. Entry criteria were: solid thyroid nodule with volume >5 and P50% in 67.3% of cases (PP=0.002) and cosmetic signs from 74 to 12% of cases. The procedure was well tolerated in most (92%) of cases. One case of vocal cord paresis self-resolved in two weeks. No changes in thyroid function were observed. In Group 2 nodule volume increased at 36 months (25±42%; P=0) and local symptoms worsened not significantly. Discussion: A single LAT treatment of solid thyroid nodules results in a significant volume reduction with improvement of local symptoms and signs. These effects are persistent on the long-term in absence of relevant side-effects or thyroid function changes.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
Long-term efficacy of ultrasound-guided laser ablation for solid thyroid nodules. A three-year multicenter prospective randomized trial
Background: Thermal ablation techniques are reported to significantly decrease thyroid nodule volume in several single-center short-term series. The present trial on ultrasound (US)-guided laser ablation (LAT) of solid thyroid nodules is addressed to assess long-term clinical efficacy, side-effects and variability of outcomes in different centers operating with the same LAT procedure. Patients: Two hundred and one consecutive patients were randomly assigned to a single LAT session (Group 1) or follow-up (Group 2) at four thyroid referral centers. Entry criteria were: solid thyroid nodule with volume >5 and P50% in 67.3% of cases (PP=0.002) and cosmetic signs from 74 to 12% of cases. The procedure was well tolerated in most (92%) of cases. One case of vocal cord paresis self-resolved in two weeks. No changes in thyroid function were observed. In Group 2 nodule volume increased at 36 months (25±42%; P=0) and local symptoms worsened not significantly. Discussion: A single LAT treatment of solid thyroid nodules results in a significant volume reduction with improvement of local symptoms and signs. These effects are persistent on the long-term in absence of relevant side-effects or thyroid function changes.
- 1 April 2013
- Published by Bioscientifica in Endocrine Abstracts
Follow-up of benign nodules
The majority of thyroid nodules do not need treatment after the exclusion of malignancy or abnormal thyroid function due to the usually slow growth rate of benign thyroid lesions. Clinical and US follow-up should be performed every 1–2 years. A repeated US-FNA is appropriate only in case of relevant nodule growth or suspicious US changes. A minority of benign nodules present a progressive growth that causes local pressure symptoms or patient’s concern. To avoid unnecessary surgery, treatment options include percutaneous ethanol injection (PEI) for recurrent cystic lesions and TSH suppression with levothyroxine (T4) or US-guided thermal ablation for solid nodules. A clinically significant decrease in nodule volume is obtained with T4 only in a minority of patients. Routine use of T4 therapy is not recommended but may be considered, with iodine supplementation, in younger patients from iodine-deficient areas who have small nodules with colloid features on cytology, or small size nodular goiters with no evidence of functional autonomy. If T4 therapy is not indicated or the nodule grows during the course of treatment, surgery or image-guided mini-invasive procedures may be considered as therapeutic options. PEI is an alternative to surgery for complex nodules with a dominant fluid component. PEI is significantly superior to aspiration alone in reducing nodule volume with a volume decrease >50% in nearly 90% of cases. For solid benign nodules that cause local symptoms or patient’s concern, percutaneous thermal ablation with laser or radiofrequency may be considered as an effective debulking technique. These outpatient procedures are rapid and do not require high-cost devices. US and US-FNA have sharply decreased the rate of diagnostic surgery. US follow-up makes possible an easy and reliable monitoring of benign thyroid nodules. Mini-invasive procedures may further reduce the number of surgical treatments for symptomatic benign nodules.
- 1 April 2013
- Published by Bioscientifica in Endocrine Abstracts
Follow-up of benign nodules
The majority of thyroid nodules do not need treatment after the exclusion of malignancy or abnormal thyroid function due to the usually slow growth rate of benign thyroid lesions. Clinical and US follow-up should be performed every 1–2 years. A repeated US-FNA is appropriate only in case of relevant nodule growth or suspicious US changes. A minority of benign nodules present a progressive growth that causes local pressure symptoms or patient’s concern. To avoid unnecessary surgery, treatment options include percutaneous ethanol injection (PEI) for recurrent cystic lesions and TSH suppression with levothyroxine (T4) or US-guided thermal ablation for solid nodules. A clinically significant decrease in nodule volume is obtained with T4 only in a minority of patients. Routine use of T4 therapy is not recommended but may be considered, with iodine supplementation, in younger patients from iodine-deficient areas who have small nodules with colloid features on cytology, or small size nodular goiters with no evidence of functional autonomy. If T4 therapy is not indicated or the nodule grows during the course of treatment, surgery or image-guided mini-invasive procedures may be considered as therapeutic options. PEI is an alternative to surgery for complex nodules with a dominant fluid component. PEI is significantly superior to aspiration alone in reducing nodule volume with a volume decrease >50% in nearly 90% of cases. For solid benign nodules that cause local symptoms or patient’s concern, percutaneous thermal ablation with laser or radiofrequency may be considered as an effective debulking technique. These outpatient procedures are rapid and do not require high-cost devices. US and US-FNA have sharply decreased the rate of diagnostic surgery. US follow-up makes possible an easy and reliable monitoring of benign thyroid nodules. Mini-invasive procedures may further reduce the number of surgical treatments for symptomatic benign nodules.